Wåhlander K - Search Results

1

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.

Wolzt M, Wollbratt M, Svensson M, Wåhlander K, Grind M, Eriksson UG. Wolzt M, et al. Among authors: wahlander k. Eur J Clin Pharmacol. 2003 Oct;59(7):537-43. doi: 10.1007/s00228-003-0667-2. Epub 2003 Sep 4. Eur J Clin Pharmacol. 2003. PMID: 12955372 Clinical Trial.

2

Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.

Wolzt M, Boström SL, Svensson M, Wåhlander K, Grind M, Sarich TC. Wolzt M, et al. Among authors: wahlander k. Pathophysiol Haemost Thromb. 2003 Mar-Apr;33(2):68-74. doi: 10.1159/000073849. Pathophysiol Haemost Thromb. 2003. PMID: 14624047 Clinical Trial.

3

Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.

Wolzt M, Levi M, Sarich TC, Boström SL, Eriksson UG, Eriksson-Lepkowska M, Svensson M, Weitz JI, Elg M, Wåhlander K. Wolzt M, et al. Among authors: wahlander k. Thromb Haemost. 2004 Jun;91(6):1090-6. doi: 10.1160/TH03-09-0605. Thromb Haemost. 2004. PMID: 15175794 Clinical Trial.

4

Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.

Cullberg M, Eriksson UG, Wåhlander K, Eriksson H, Schulman S, Karlsson MO. Cullberg M, et al. Among authors: wahlander k. Clin Pharmacol Ther. 2005 Apr;77(4):279-90. doi: 10.1016/j.clpt.2004.11.001. Clin Pharmacol Ther. 2005. PMID: 15903126 Clinical Trial.

5

Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837.

Schützer KM, Svensson MK, Zetterstrand S, Eriksson UG, Wåhlander K. Schützer KM, et al. Among authors: wahlander k. Eur J Clin Pharmacol. 2010 Sep;66(9):903-10. doi: 10.1007/s00228-010-0849-7. Epub 2010 Jun 10. Eur J Clin Pharmacol. 2010. PMID: 20535457 Free article. Clinical Trial.

6

Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.

Wolzt M, Eriksson UG, Gouya G, Leuchten N, Kapiotis S, Elg M, Schützer KM, Zetterstrand S, Holmberg M, Wåhlander K. Wolzt M, et al. Among authors: wahlander k. Thromb Res. 2012 Apr;129(4):e83-91. doi: 10.1016/j.thromres.2011.08.018. Epub 2011 Sep 16. Thromb Res. 2012. PMID: 21925716 Clinical Trial.

7

Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation.

Lip GY, Rasmussen LH, Olsson SB, Jensen E, Hamrén B, Eriksson UG, Wåhlander K. Lip GY, et al. Among authors: wahlander k. Br J Clin Pharmacol. 2015 Dec;80(6):1362-73. doi: 10.1111/bcp.12719. Epub 2015 Sep 22. Br J Clin Pharmacol. 2015. PMID: 26174611 Free PMC article. Clinical Trial.

8

Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Johansson S, Cullberg M, Eriksson UG, Elg M, Dunér K, Jensen E, Wollbratt M, Wåhlander K. Johansson S, et al. Among authors: wahlander k. Int J Clin Pharmacol Ther. 2011 Apr;49(4):258-67. doi: 10.5414/CP201465. Int J Clin Pharmacol Ther. 2011. PMID: 21429440

9

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.

Wåhlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H. Wåhlander K, et al. Thromb Res. 2002 Aug 15;107(3-4):93-9. doi: 10.1016/s0049-3848(02)00259-1. Thromb Res. 2002. PMID: 12431473 Clinical Trial.

10

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Wåhlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. Wåhlander K, et al. Clin Pharmacokinet. 2003;42(8):755-64. doi: 10.2165/00003088-200342080-00004. Clin Pharmacokinet. 2003. PMID: 12846596 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters